Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer.

Samuel Martel; Elena Poletto; Arlindo R Ferreira; Matteo Lambertini; Federico Sottotetti; Ilaria Bertolini; Filippo Montemurro; Antonio Bernardo; Emanuela Risi; Elisa Zanardi; Serena Ziliani; Silvia Mura; Chiara Dellepiane; Lucia Del Mastro; Alessandro Marco Minisini; Fabio Puglisi

doi:10.1016/j.breast.2017.11.004

Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer.

Samuel Martel, Elena Poletto, Arlindo R Ferreira, Matteo Lambertini, Federico Sottotetti, Ilaria Bertolini, Filippo Montemurro, Antonio Bernardo, Emanuela Risi, Elisa Zanardi, Serena Ziliani, Silvia Mura, Chiara Dellepiane, Lucia Del Mastro, Alessandro Marco Minisini, Fabio Puglisi

Istituto Oncologico Candiolo

Research output: Contribution to journal › Article › peer-review

Abstract

Overweight and obesity are associated with an increased risk of developing many types of cancer, including breast cancer. Moreover, increased body mass index (BMI) seems to be associated with a worse prognosis in patients with HER2-positive early breast cancer. However, little is known about the impact of BMI on the clinical outcomes of HER2-positive metastatic breast cancer (MBC). This was a multicenter retrospective cohort study including 329 consecutive patients with HER2-positive MBC treated with first-line trastuzumab-based regimens. BMI at the time of MBC diagnosis was collected. World Health Organization BMI categories were used: underweight

Original language	Undefined/Unknown
Pages (from-to)	142-147
Number of pages	6
Journal	Breast
Volume	37
DOIs	https://doi.org/10.1016/j.breast.2017.11.004
Publication status	Published - Feb 1 2018

Keywords

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols, therapeutic use
Body Mass Index
Breast Neoplasms, drug therapy, metabolism, pathology
Disease-Free Survival
Female
Humans
Kaplan-Meier Estimate
Middle Aged
Neoplasm Metastasis
Proportional Hazards Models
Receptor, ErbB-2, metabolism
Retrospective Studies
Survival Rate
Trastuzumab, administration & dosage
Treatment Outcome
Body mass index
HER2-positive
Metastatic breast cancer
Trastuzumab

Access to Document

10.1016/j.breast.2017.11.004

Cite this

Martel, S., Poletto, E., Ferreira, A. R., Lambertini, M., Sottotetti, F., Bertolini, I., Montemurro, F., Bernardo, A., Risi, E., Zanardi, E., Ziliani, S., Mura, S., Dellepiane, C., Del Mastro, L., Minisini, A. M., & Puglisi, F. (2018). Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer. Breast, 37, 142-147. https://doi.org/10.1016/j.breast.2017.11.004

Martel, S, Poletto, E, Ferreira, AR, Lambertini, M, Sottotetti, F, Bertolini, I, Montemurro, F, Bernardo, A, Risi, E, Zanardi, E, Ziliani, S, Mura, S, Dellepiane, C, Del Mastro, L, Minisini, AM & Puglisi, F 2018, 'Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer.', Breast, vol. 37, pp. 142-147. https://doi.org/10.1016/j.breast.2017.11.004

@article{b36193229f2048db95cfc89e82cba1c0,

title = "Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer.",

abstract = "Overweight and obesity are associated with an increased risk of developing many types of cancer, including breast cancer. Moreover, increased body mass index (BMI) seems to be associated with a worse prognosis in patients with HER2-positive early breast cancer. However, little is known about the impact of BMI on the clinical outcomes of HER2-positive metastatic breast cancer (MBC). This was a multicenter retrospective cohort study including 329 consecutive patients with HER2-positive MBC treated with first-line trastuzumab-based regimens. BMI at the time of MBC diagnosis was collected. World Health Organization BMI categories were used: underweight ",

keywords = "Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Body Mass Index, Breast Neoplasms, drug therapy, metabolism, pathology, Disease-Free Survival, Female, Humans, Kaplan-Meier Estimate, Middle Aged, Neoplasm Metastasis, Proportional Hazards Models, Receptor, ErbB-2, metabolism, Retrospective Studies, Survival Rate, Trastuzumab, administration & dosage, Treatment Outcome, Body mass index, HER2-positive, Metastatic breast cancer, Trastuzumab",

author = "Samuel Martel and Elena Poletto and Ferreira, {Arlindo R} and Matteo Lambertini and Federico Sottotetti and Ilaria Bertolini and Filippo Montemurro and Antonio Bernardo and Emanuela Risi and Elisa Zanardi and Serena Ziliani and Silvia Mura and Chiara Dellepiane and {Del Mastro}, Lucia and Minisini, {Alessandro Marco} and Fabio Puglisi",

year = "2018",

month = feb,

day = "1",

doi = "10.1016/j.breast.2017.11.004",

language = "Non definita",

volume = "37",

pages = "142--147",

journal = "Breast",

issn = "0960-9776",

publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer.

AU - Martel, Samuel

AU - Poletto, Elena

AU - Ferreira, Arlindo R

AU - Lambertini, Matteo

AU - Sottotetti, Federico

AU - Bertolini, Ilaria

AU - Montemurro, Filippo

AU - Bernardo, Antonio

AU - Risi, Emanuela

AU - Zanardi, Elisa

AU - Ziliani, Serena

AU - Mura, Silvia

AU - Dellepiane, Chiara

AU - Del Mastro, Lucia

AU - Minisini, Alessandro Marco

AU - Puglisi, Fabio

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Overweight and obesity are associated with an increased risk of developing many types of cancer, including breast cancer. Moreover, increased body mass index (BMI) seems to be associated with a worse prognosis in patients with HER2-positive early breast cancer. However, little is known about the impact of BMI on the clinical outcomes of HER2-positive metastatic breast cancer (MBC). This was a multicenter retrospective cohort study including 329 consecutive patients with HER2-positive MBC treated with first-line trastuzumab-based regimens. BMI at the time of MBC diagnosis was collected. World Health Organization BMI categories were used: underweight

AB - Overweight and obesity are associated with an increased risk of developing many types of cancer, including breast cancer. Moreover, increased body mass index (BMI) seems to be associated with a worse prognosis in patients with HER2-positive early breast cancer. However, little is known about the impact of BMI on the clinical outcomes of HER2-positive metastatic breast cancer (MBC). This was a multicenter retrospective cohort study including 329 consecutive patients with HER2-positive MBC treated with first-line trastuzumab-based regimens. BMI at the time of MBC diagnosis was collected. World Health Organization BMI categories were used: underweight

KW - Adult

KW - Aged

KW - Antineoplastic Combined Chemotherapy Protocols, therapeutic use

KW - Body Mass Index

KW - Breast Neoplasms, drug therapy, metabolism, pathology

KW - Disease-Free Survival

KW - Female

KW - Humans

KW - Kaplan-Meier Estimate

KW - Middle Aged

KW - Neoplasm Metastasis

KW - Proportional Hazards Models

KW - Receptor, ErbB-2, metabolism

KW - Retrospective Studies

KW - Survival Rate

KW - Trastuzumab, administration & dosage

KW - Treatment Outcome

KW - Body mass index

KW - HER2-positive

KW - Metastatic breast cancer

KW - Trastuzumab

U2 - 10.1016/j.breast.2017.11.004

DO - 10.1016/j.breast.2017.11.004

M3 - Articolo

VL - 37

SP - 142

EP - 147

JO - Breast

JF - Breast

SN - 0960-9776

ER -